相关实验视频
Updated: Jul 15, 2026

06:59
Quantification of Atherosclerosis in Mice
Published on: June 12, 2019
在低密度脂蛋白受体-淘汰赛小鼠中,甲素L缺乏会降低饮食诱导的动脉样硬化
Shiro Kitamoto1, Galina K Sukhova, Jiusong Sun
1Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass, USA.
Circulation
|April 4, 2007
概括
甲素L (Cat L) 酶缺乏,通过限制动脉基质降解和白细胞透,减少小鼠动脉样硬化发展. 这项研究强调了Cat L作为治疗心血管疾病的关键目标.
科学领域:
- 心血管生物学 心血管生物学
- 酶学 是一种酶学.
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 动脉细胞外矩阵重塑在动脉样硬化中至关重要.
- 甲素L (Cat L) 是一种弹性溶解和原溶解酶,在人类动脉样硬化病变中被上调调节.
研究的目的:
- 在动脉样硬化的小鼠模型中研究Cat L的作用.
- 为了确定Cat L缺乏是否会影响病变的发展和细胞外基质的降解.
主要方法:
- 通过杂交产生双缺LDLr-/- 类型L-/- 的小鼠.
- 给小鼠食用西方饮食12周和26周.
- 评估病变的大小,组成和白细胞透情况.
- 进行了关于光滑肌肉细胞和白细胞转移的体外研究.
主要成果:
- LDLr-/- Cat L-/-小鼠表现出显著较小的动脉样硬化病变和脂质核.
- 在病变中减少原蛋白,弹性质降解和炎症细胞透 (T细胞,巨细胞,光滑肌细胞).
- 在体外,L类缺乏会损害平滑肌细胞的细胞外基质降解和白细胞通过原基质的转移.
- 类型L缺乏症不会影响其他与动脉样硬化相关的甲素的活性.
结论:
- 卡塞普辛L直接导致动脉样硬化的进展.
- Cat L 降解了弹性质和原,促进了白细胞的转移.
- 准L类可能为动脉样硬化提供治疗策略.
相关概念视频
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
